Figure 3.

Primary outcome variables: cancer-related anxiety and depression (pre-crossover).

Means (±SE) for primary outcome measures are shown in the two treatment groups at the following time points: baseline (psilocybin first n=14, niacin first n=15), 1 day pre-dose 1 (psilocybin first n=14, niacin first n=15), 1 day post-dose 1 (psilocybin first n=14, niacin first n=15), 2 weeks post-dose 1 (psilocybin first n=14, niacin first n=14), 6 weeks post-dose 1 (psilocybin first n=14, niacin first n=14), 7 weeks post-dose 1 (psilocybin first n=12, niacin first n=14). Asterisks indicate significance level of between-group t-tests. Effect sizes, represented as Cohen’s d, are shown above time points at which the treatment groups differ. Closed points represent significant within-group differences relative to scores at baseline.